Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 amp FGFR2 mut Debio 1347 cervical adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01101451 Phase III Cisplatin Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Active, not recruiting USA 2
NCT02257528 Phase II Nivolumab Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Active, not recruiting USA 0
NCT02348398 Phase II Pazopanib + Topotecan Phase II Study of Pazopanib and Topotecan in Cervical Cancer Withdrawn 0
NCT02466971 Phase III Cisplatin Cisplatin + Triapine Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers Active, not recruiting USA | CAN 1
NCT02584478 Phase Ib/II Anlotinib + Carboplatin + Paclitaxel Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) Active, not recruiting USA | ITA | GBR | ESP 2
NCT02595879 Phase I Cisplatin + Triapine Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer Active, not recruiting USA 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02853604 Phase III ADXS11-001 Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV) Terminated USA | ESP | CAN 11
NCT03108495 Phase II LN-145 Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma Recruiting USA | ITA | GBR | FRA | ESP | DEU 2
NCT03367871 Phase II Cisplatin + Paclitaxel + Pembrolizumab Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer Terminated USA 0
NCT03438396 Phase II Tisotumab vedotin-tftv A Trial of Tisotumab Vedotin in Cervical Cancer Completed USA | ITA | ESP | DEU | BEL 3
NCT03495882 Phase Ib/II Balstilimab + Zalifrelimab Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) Completed USA | ESP | AUS 6
NCT03556839 Phase III Atezolizumab + Bevacizumab + Cisplatin + Paclitaxel Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) Active, not recruiting USA | ITA | FRA | ESP | DEU 3
NCT03612791 Phase II Cisplatin Atezolizumab + Cisplatin Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC) Recruiting FRA 0
NCT03635567 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Cisplatin + Paclitaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Cisplatin + Paclitaxel + Pembrolizumab Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) Active, not recruiting USA | ITA | FRA | ESP | DEU | CAN | AUS 12
NCT03644342 Phase Ib/II Niraparib Study of Niraparib With Radiotherapy for Treatment of Metastatic Invasive Carcinoma of the Cervix (NIVIX) Suspended USA 0
NCT03738228 Phase I Atezolizumab + Cisplatin Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer Active, not recruiting USA 0
NCT03786081 Phase Ib/II Bevacizumab + Tisotumab vedotin-tftv Carboplatin + Tisotumab vedotin-tftv Pembrolizumab + Tisotumab vedotin-tftv Safety and Efficacy of Tisotumab Vedotin in Combination With Other Cancer Agents in Subjects With Cervical Cancer Active, not recruiting USA | ITA | GBR | ESP | BEL 5
NCT03830866 Phase III Durvalumab Cisplatin + Durvalumab Carboplatin + Durvalumab Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA) (CALLA) Completed USA 14
NCT03833479 Phase II Dostarlimab-gxly TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC) (ATOMICC) Active, not recruiting ESP 1
NCT03894215 Phase II Balstilimab Balstilimab + Zalifrelimab Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer Active, not recruiting USA 6
NCT04065269 Phase II Ceralasertib + Olaparib Ceralasertib ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI) Unknown status GBR 0
NCT04205799 Phase II Cabozantinib Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure (CABOCOL-01) Completed FRA 0
NCT04221945 Phase III Cisplatin + Pembrolizumab Cisplatin Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 20
NCT04230954 Phase II Cabozantinib + Pembrolizumab Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer Terminated USA 0
NCT04238988 Phase II Carboplatin + Paclitaxel + Pembrolizumab Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer (MITO CERV 3) Unknown status ITA 0
NCT04246489 Phase II Bintrafusp alfa Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer Completed USA | FRA | ESP | BEL | AUS 7
NCT04300647 Phase II Atezolizumab Atezolizumab + Tiragolumab A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04) Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 10
NCT04381650 Phase Ib/II Pembrolizumab + Subasumstat A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Recruiting USA 9
NCT04405349 Phase II Atezolizumab + VB10.16 Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer Active, not recruiting DEU | BEL 4
NCT04487587 Phase II Cediranib + Olaparib A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer (COMICE) Unknown status GBR 0
NCT04551950 Phase I Bevacizumab + Bintrafusp alfa + Carboplatin + Paclitaxel Bevacizumab + Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin + Paclitaxel Bintrafusp alfa + Cisplatin Bintrafusp alfa + Carboplatin + Paclitaxel Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTRAPID 046) Completed USA | ESP 1
NCT04630353 Phase I HB-201 A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer Recruiting USA 0
NCT04652076 Phase Ib/II Carboplatin + NP137 + Paclitaxel Trevatide + Pembrolizumab NP137 + Pembrolizumab Carboplatin + NP137 + Paclitaxel Carboplatin + Paclitaxel GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or Pembrolizumab (GYNET) Recruiting FRA 0
NCT04697628 Phase III Topotecan Gemcitabine Irinotecan Tisotumab vedotin-tftv Pemetrexed Disodium Vinorelbine Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer (innovaTV 301) Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 18
NCT04943627 Phase III Topotecan Balstilimab Gemcitabine Irinotecan Pemetrexed Disodium Vinorelbine Balstilimab in Patients With Recurrent Cervical Cancer. Withdrawn USA 1
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) Recruiting USA | ITA | FRA | ESP | DEU | CAN 9
NCT05337735 Phase II XmAb20717 A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Recruiting USA 0
NCT05475171 Phase II MGD019 Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) Recruiting USA 0
NCT05521997 Phase II Cisplatin + Telaglenastat Cisplatin Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer Not yet recruiting USA 0
NCT05784688 Phase Ib/II Pembrolizumab + TU2218 Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT06079671 Phase III MEDI5752 Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) (eVOLVECervical) Recruiting USA | ESP | CAN 8